EPSRC – Internal Deadline: 13 Jul 2018

Strategic Equipment Process

Strategic Equipment is intended to enhance UK scientific capability and support a portfolio of high-quality, cutting-edge research of high priority to EPSRC; it can include both existing and potential research projects. The request should fit with the host university strategy and enable research that predominantly falls within EPSRC‘s remit. This scheme can fund individual or combined assets with a value over £400,000. Strategic Equipment could include, but is not limited to, enabling technology that increases novel research capability, or high-specification equipment that enables research through increased capacity (e.g. faster, higher resolution or more cost-effective results). Applications for Strategic Equipment should not include underpinning equipment that we would expect to see in a well-found lab.

EPSRC strongly encourages a strategic approach to the submission of business cases and therefore the College has agreed the following internal selection process, in an effort to manage the timing of bids for maximal success and to provide an opportunity for Professor Nick Jennings, Vice-Provost (Research and Enterprise), to offer institutional approval to bids and agree to be named as a co-I, which EPSRC requires him to be.


Deadline Key stage
noon Friday 13 July 2018 College process: candidates submit outline proposals to Suzanne Rolfe (s.rolfe@imperial.ac.uk)
Tuesday 24 July 2018 College process: CCRPRG review outlines and form recommendations for selection. Decisions announced as soon as possible after this date
Wednesday 29 August 2018 College process: Research Services 5 day deadline for candidate to submit to RS
Wednesday 5 September 2018 EPSRC deadline for outline submissions
Sept/Oct 2018 EPSRC Outline Panel date
Not known* EPSRC deadline for full applications
March 2019 EPSRC Interview Panel date

College contact: Suzanne Rolfe (s.rolfe@imperial.ac.uk). For more information please visit the EPSRC website.


British Lung Foundation – 16 Jul 2018

Travel Awards

The British Lung Foundation offers travel awards to the European Respiratory Society and American Thoracic Society Conferences. These travel awards are available to early-career clinical and/or non-clinical researchers in the respiratory field and contribute towards the costs of registration, accommodation and travel to assist in the attendance of these important meetings.

European Respiratory Society conference

This year we are offering travel award types to the ERS International Congress in Paris, 15-19 September 2018:

  1. British Lung Foundation awards and British Lung Foundation – British Paediatric Respiratory Society awards
  2. British Lung Foundation – NAPP Pharmaceuticals Ltd awards
  3. British Lung Foundation – King’s College London respiratory and sleep physiology fellowship (travel) award

1. British Lung Foundation awards and British Lung Foundation – British Paediatric Respiratory Society awards

4 British Lung Foundation Travel Fellowships worth £750 each are available for early-career clinical and non-clinical researchers in the respiratory field to attend the European Respiratory Society International Congress 2018.

In addition, the British Lung Foundation and the British Paediatric Respiratory Society (BPRS) are co-funding 2 ERS Travel Fellowships of £750 each, available to paediatric respiratory researchers, with preference to those who have been a member of the BPRS for a minimum of 12 months.

2. British Lung Foundation – NAPP Pharmaceuticals Ltd awards

10 British Lung Foundation-Napp Pharmaceuticals Limited Travel Fellowships worth £750 each are available for early-career health care professionals conducting research in the respiratory field in the UK to attend the European Respiratory Society International Congress 2018. Please read the accompanying guidelines before completing an application form.

3. British Lung Foundation – King’s College London respiratory and sleep physiology fellowship (travel) award

One British Lung Foundation-King’s College London Travel Fellowship worth £750 is available for early-career clinical and non-clinical researchers working in the respiratory and sleep physiology field to attend the European Respiratory Society International Congress 2018. Please read the accompanying guidelines before completing an application form.

Funding decisions will be made known to all applicants by late August/early September 2018. For more information please visit the BLF website.

British Society for Allergy and Clinical Immunology – Deadline 23 Jul 2018

Travel fellowship scheme

These assist with attendance at the annual meeting. Applications from both BSACI and non BSACI members are accepted . If your application is accepted you could receive the following funding depending on the number of nights you will be staying.

One night stay = £200

Two nights stay = £300

Three nights stay = £400

We are proud that this scheme is supporting an increase in attendance and involvement amongst students and healthcare professionals who have less access to financial resources. With the increasing number of Travel Fellowship applications, we are limiting applications to delegates submitting accepted abstracts who are trainees, students, nurses or allied health professionals. When allocating funds priority will be given to BSACI members. Fellowships will be awarded on the grounds of those perceived to be in most financial need or having incurred the greatest expense to attend, rather than on the particular strength of their abstract itself. This is consistent with our wish to make the annual meeting as inclusive as possible. In 2017 the average level of funds allocated was between £200 and £250. If you have any questions please contact bsaci@medivents.co.uk

How to apply

Please send an email to bsaci@medivents.co.uk no later than 9am on Monday 23rd July to include the following:

  1. A supporting letter from your head of department
  2. Covering letter from yourself indicating the number of nights you are staying.
  3. Confirmation of your accepted abstract

You will be notified of the outcome of your application by email around 1st August. If you are successful your travel and accommodation costs will be reimbursed up to your allocated amount on production of relevant receipts after the Meeting.

If you want to know more about this scheme please visit the BSACI website.

CRUK – Deadline: 24 Jul 2018

Multidisciplinary Project Award

This scheme, co-funded by the EPSRC, supports collaborations between cancer researchers and scientists from engineering/physical science disciplines.

MRC – Deadline: 25 Jul 2018

Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS)

The DPFS scheme is a key part of our Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.


The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.

Projects supported by the scheme have up to four clearly defined milestones, outcomes and future plans. These help to maximise both the chance of success and the likelihood of the project attracting the downstream funding, from public or private sources, required to meet its clinical and commercial aims. The funding panels assessing the project will, if necessary, help to develop proposals and suggest enhancements.

The following activities are eligible for support:

  • Developing candidate therapeutic entities (e.g. drug discovery)
  • Pre-clinical testing of novel therapeutic entities
  • Early-phase clinical studies of novel therapeutic entities (phases 1 and 2)
  • “Repurposing” clinical studies – using existing therapies for new indications
  • Developing and testing novel devices
  • Developing and testing diagnostics (including biomarker validation)

Individual projects can start and finish at any point along the translational pathway but would not typically progress from initial development through to phase 2 clinical testing in a single application. Where there is a justified need for continued MRC support, sequential applications are encouraged.

All disease areas (including those relevant to global health) and modalities of intervention are eligible for support from the scheme, including small molecules, peptides, antibodies, vaccines, cell and gene therapy, devices, surgical techniques and psychological approaches.


For more information please visit the MRC website.

Action for A-T – Deadline: 26 Jul 2018

MRC Harwell: Deadline 27 Jul 2018

Genome editing mice for medicine grant

The Harwell international centre for mouse genetics, under the Medical Research Council, invites nominations for its . This supports the production of genetically modified mouse lines that advance knowledge of human disease or are of widespread use in biomedical science. Nominations should consider specific genetic alterations in the mouse using genome editing technologies. They will be assessed by the nominator’s own research hypotheses and plans for utilising the mouse as well as by the impact the proposed novel mouse line will have on the academic community. In addition to single mouse lines, nominations for collections or groups of lines within specific theme or discipline will be considered. The following allele types or methodologies are available: indels, deletions, point mutation insertions, cassette knock-ins and conditional or Tm1a allele generation.

Researchers and groups based in UK higher education institutes, independent research organisations, government-funded organisations, university units and MRC units and institutes may nominate. They must have necessary interests, expertise, licences and facilities to work with animals and carry out the research. Collaborations and team approaches are encouraged.

The total budget is worth £4.5 million over five years. The award covers mouse line generation and archiving but not other research costs. For more information visit the GEMM website.

AstraZeneca – Deadline 1 Aug 2018

Novel Disease Mechanisms for AstraZeneca Preclinical Compounds – innocentive Challenge

AstraZeneca is in the unique position to provide a selection of high-quality tool compounds to create valuable opportunities to explore disease biology in the preclinical setting. AstraZeneca desires proposals that link one or more of these compounds to the following therapeutic areas: respiratory disease, cardiovascular disease, renal disease, or diabetes.

AstraZeneca intends to make up to 5 awards from a total award pool of $50,000. Winning proposals could be selected to receive up to $50,000 in additional research funding.

Pharmaceutical R&D faces several significant challenges in terms of identifying drug targets that translate from basic science into clinical projects and then ultimately into medicines that make a difference to the lives of patients. For every medicine that is prescribed, there are many other drug candidates which do not reach the approval stage. Some of these molecules have been studied extensively and their behavior is well characterized in vitro and in vivo. The availability of high-quality tool compounds enables potential mechanisms of disease to be investigated that may provide novel insights into the biology of the disease and hopefully better translation into the clinic.

This Theoretical Challenge requires only a written proposal. For more information please visit the Innocentive webpage.

Wellcome Trust – Deadline: 13 Aug 2018

Clinical Research Career Development Fellowships

This scheme enables medical, dental, veterinary and clinical psychology graduates to continue their research at postdoctoral level and develop scientific independence. It provides support for up to eight years and the flexibility to balance research and clinical responsibilities.

Applications for this scheme are considered twice a year.

For more information about this fellowship please visit the Wellcome Trust website.


BHF – Deadline: 15 Aug 2018

Clinical Study Grants

For clinical trials and observational studies of specific patient groups costing more than £300,000 or lasting more than 3 years.

Award specifications

The clinical study grant supports funding for over £300,000 for:

  • Interventional clinical trials: trials of specific interventions or pathways of care for the prevention, diagnosis and treatment of cardiovascular disease. Interventions include drugs, surgery, devices, psychological, physical and educational interventions.
  • Observational studies of specific patient groups that are hypothesis led and address a defined clinical question(s) over a fixed timescale (up to 5 years). The population of interest should be a patient population, who will usually be recruited within the NHS. The study should have a predefined outcome(s) that will lead to changes in clinical management directly or will inform the development of a clinical trial to test an intervention.
  • Clinical studies can include a mechanistic evaluation, either as a substudy within a clinical trial or as part of an observational study.

The scheme does not support funding for population based cohort studies or patient based cohort studies focusing on open ended epidemiological questions, or whose main focus is genetics/genomics or other omics analyses (please apply for either a Special Project Grant or a Programme Grant). For programmes of experimental medicine or programmes of clinical research, please apply for a Programme Grant.

How to apply

Applications are assessed in a two stage process: an outline application followed by a full application if the outline is successful. Outline applications are considered throughout the year, and you will usually receive a decision on submitting a full application within 6 weeks of the outline submission.

For more information please visit the BHF website.